NasdaqGM:RLAYBiotechs
Zovegalisib’s Consistent Efficacy Across Tough Subgroups Could Be A Game Changer For Relay (RLAY)
Relay Therapeutics, Inc. recently presented a subset analysis of interim data from its first-in-human ReDiscover trial, highlighting zovegalisib’s efficacy and tolerability in heavily pretreated HR+/HER2- advanced breast cancer patients at the 2025 San Antonio Breast Cancer Symposium.
The data showed consistent progression-free survival and response rates across challenging subgroups, such as prior SERD exposure and ESR1-mutated tumors, reinforcing interest in this allosteric PI3Ka...